5-Amino-1MQ – Comprehensive Research Overview (2026)

5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). It is researched primarily for its ability to enhance fat metabolism, improve insulin sensitivity, and support cellular energy efficiency by preserving NAD⁺ levels and increasing the SAM/SAH ratio. Unlike appetite-suppressing compounds, 5-Amino-1MQ works by reprogramming adipose tissue metabolism, making it a unique candidate in metabolic health, obesity, and longevity research.

→ View 5-Amino-1MQ (for laboratory research use only)

Chemical Structure and Properties

  • Chemical Name: 5-Amino-1-methylquinolinium
  • Molecular Formula: C₁₀H₁₁N₂⁺ (cation)
  • Molecular Weight: ≈159–176 g/mol (depending on salt form)
  • Form: Oral capsule or research powder (highly water-soluble and cell-permeable)
  • Key Feature: Selective NNMT inhibitor with good membrane permeability

Mechanism of Action

5-Amino-1MQ selectively inhibits NNMT, an enzyme upregulated in obesity and aging that consumes nicotinamide and SAM. By blocking this pathway:

  • NAD⁺ levels are preserved and elevated
  • SAM availability increases, supporting methylation reactions
  • Adipocytes shift from lipid storage toward oxidative metabolism and energy expenditure
  • Mitochondrial function and metabolic flexibility improve

This creates a metabolic reprogramming effect similar to calorie restriction or exercise without reducing food intake in preclinical models.

Clinical Evidence and Research Findings

  • Strong preclinical data in diet-induced obesity (DIO) mouse models: significant reductions in body weight, fat mass, and adipocyte size, plus improved cholesterol and metabolic markers.
  • No large-scale human clinical trials published as of April 2026.
  • Early anecdotal and practitioner reports note improvements in body composition, energy, and metabolic health when combined with diet and exercise.
  • Remains an investigational compound with promising mechanistic and animal data but limited human evidence.

→ Interested in researching 5-Amino-1MQ? View Product Options

Benefits (Research & Clinical Observations)

  • Targeted fat loss, particularly visceral and stubborn adipose tissue
  • Improved insulin sensitivity and glucose metabolism
  • Support for NAD⁺-related cellular energy and longevity pathways
  • Potential synergy with other metabolic agents (e.g., NAD⁺ precursors, exercise mimetics)

Typical Dosing Protocols (Off-Label / Compounded)

  • Common protocols: 50–150 mg per day (often split into 1–2 doses)
  • Many users start at 50–75 mg and titrate based on tolerance
  • Cycles: Typically 4–8 weeks on, followed by equal or longer breaks
  • Best taken with meals; often combined with diet and resistance training

Safety Profile and Side Effects

Preclinical toxicology shows a favorable short-term profile with no major organ toxicity at effective doses.

Reported side effects (anecdotal): Mild digestive changes or headaches (usually transient). No significant appetite suppression.

Monitoring recommended: Liver enzymes, glucose, and metabolic panels with prolonged use. Long-term human safety data are limited.

Summary

5-Amino-1MQ is a selective NNMT inhibitor with compelling preclinical evidence for fat loss, metabolic reprogramming, and cellular energy support. Its unique mechanism offers a complementary approach in the metabolic and longevity research space. As with all compounds in this library, 5-Amino-1MQ is not an approved drug and should only be considered under qualified medical supervision with appropriate lab monitoring.

For Laboratory Research Use View 5-Amino-1MQ →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.